Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ABMD

Abiomed (ABMD) Stock Price, News & Analysis

Abiomed logo

About Abiomed Stock (NASDAQ:ABMD)

Key Stats

Today's Range
$381.02
$381.02
50-Day Range
$377.20
$381.30
52-Week Range
$219.85
$381.99
Volume
258 shs
Average Volume
611,028 shs
Market Capitalization
$17.18 billion
P/E Ratio
65.47
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

Receive ABMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abiomed and its competitors with MarketBeat's FREE daily newsletter.

ABMD Stock News Headlines

We recommended Nvidia in 2016, now we’re recommending this…
The AI boom is just getting started. And the real wealth has still to be made…
See More Headlines

ABMD Stock Analysis - Frequently Asked Questions

Abiomed, Inc. (NASDAQ:ABMD) announced its quarterly earnings data on Wednesday, October, 27th. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $0.98 by $0.05. The company's quarterly revenue was up 18.3% on a year-over-year basis.
Read the conference call transcript
.

Abiomed subsidiaries include these companies: ECP Entwicklungsgesellschaft mbH, Impella Cardiosystems, ABD Holding Company, ABIOMED Athlone Ltd, ABIOMED Australia Pte. Ltd, ABIOMED Europe, ABIOMED Japan KK, and more.

Based on aggregate information from My MarketBeat watchlists, some other companies that Abiomed investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), Visa (V) and Home Depot (HD).

Company Calendar

Last Earnings
10/27/2021
Today
11/23/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:ABMD
CUSIP
00365410
Employees
2,003
Year Founded
1981

Profitability

Net Income
$136.51 million
Pretax Margin
31.76%

Debt

Sales & Book Value

Annual Sales
$1.03 billion
Cash Flow
$5.09 per share
Book Value
$33.03 per share

Miscellaneous

Free Float
43,964,000
Market Cap
$17.18 billion
Optionable
Optionable
Beta
1.40

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:ABMD) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners